Drug Profile
Elsubrutinib - AbbVie
Alternative Names: ABBV-105Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator AbbVie
- Class Anti-inflammatories; Antirheumatics; Indoles; Piperidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 03 Jan 2024 AbbVie completes a phase II trial in Systemic lupus erythematosus (Combination therapy, In adults) in Argentina, Australia, Bulgaria, Colombia, China, Germany, Hungary, Japan, Italy, Mexico, South Korea, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom and USA (PO) (NCT04451772)
- 31 May 2023 Efficacy and adverse events data from a phase II SLEek trial in Systemic lupus erythematosus presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 14 Jul 2022 AbbVie completes the phase II SLEek trial in Systemic lupus erythematosus (In adults, In the elderly) in United Kingdom, Taiwan, Spain, Puerto Rico, Poland, New Zealand, Netherlands, South Korea, Mexico, Japan, Italy, Hungary, Germany, France, Colombia, China, Canada, Bulgaria, Australia, Argentina and USA (PO) (NCT03978520) (EudraCT2019-000638-20)